Loading clinical trials...
Loading clinical trials...
A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia
Conditions
Interventions
Tociliuzumab
Locations
24
United States
Mayo Clinic - Arizona
Phoenix, Arizona, United States
St. Jude Medical Center
Fullerton, California, United States
LAC + USC Medical Center
Los Angeles, California, United States
USC Keck Medical Center of USC
Los Angeles, California, United States
Norwalk Hospital
Norwalk, Connecticut, United States
Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Start Date
May 5, 2020
Primary Completion Date
August 12, 2020
Completion Date
August 12, 2020
Last Updated
August 31, 2022
NCT06402318
NCT06927622
NCT05706454
NCT05408312
NCT04193878
NCT05531032
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions